Norris Medicines narrows FY26 net loss to ₹28.06 lakh

1 min read Updated on 30 May 2026, 07:10 PM

Reviewed by

Suketu GScanX News Team

AI Summary

Norris Medicines Limited reduced its net loss to ₹28.06 lakh in FY26 from ₹123.75 lakh in the prior year, supported by a 39% increase in total income to ₹817.74 lakh. For the quarter ended March 31, 2026, the company reported a profit after tax of ₹5.06 lakh, reversing a loss of ₹22.85 lakh in the same period last year. The board approved the audited financial results on May 30, 2026, and appointed M/s. Dhiren Y Parikh & Co. as internal auditors for FY 2026–2027.

*this image is generated using AI for illustrative purposes only.

Norris Medicines Limited narrowed its net loss to ₹28.06 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹123.75 lakh in the previous year. The company reported total income from operations of ₹817.74 lakh for FY26, up from ₹588.15 lakh in FY25, while total expenses increased to ₹845.80 lakh from ₹705.96 lakh. The board of directors approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026, at the registered office in Ankleshwar, Gujarat.

For the quarter ended March 31, 2026, the company posted a profit after tax of ₹5.06 lakh, reversing from a loss of ₹22.85 lakh in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹140.84 lakh, down from ₹272.09 lakh in the corresponding period last year. M/s. Bahedia & Associates, Statutory Auditors, issued an unmodified opinion on the standalone financial results. The board also appointed M/s. Dhiren Y Parikh & Co., Chartered Accountants, as internal auditors for FY 2026–2027.

Financial Performance for FY26

Particulars	Year Ended 31.03.2026 (₹ in Lakhs)	Year Ended 31.03.2025 (₹ in Lakhs)
Revenue from Operations	813.20	582.02
Total Income	817.74	588.15
Total Expenses	845.80	705.96
Profit/Loss before Tax	-28.06	-117.81
Net Profit/Loss	-28.06	-123.75

Key Meeting Outcomes

Particulars	Details
Meeting Date	May 30, 2026
Venue	Registered Office, Ankleshwar, Gujarat
Auditors' Opinion	Unmodified
Internal Auditor Appointment	M/s. Dhiren Y Parikh & Co. for FY 2026–2027

Historical Stock Returns for Norris Medicines

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-8.21%	-6.20%	-6.60%	-8.33%	-31.67%	+50.57%

What strategic initiatives will Norris Medicines implement to bridge the gap between rising expenses and operational income?

How does the company plan to sustain the profitability seen in Q4 FY26 despite the significant year-on-year revenue decline?

Will the improved full-year financial performance influence the board's decision on potential dividend payouts or capital expansion?

Board Meeting Details

The board meeting was conducted pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The meeting provided a comprehensive review of the company's financial performance for the specified period.

Meeting Details:	Information
Date:	February 14, 2026
Start Time:	3:15 P.M.
End Time:	3:45 P.M.
Duration:	30 minutes
Scrip Code:	524414

Financial Results Approval

The Board of Directors considered and approved the unaudited financial results along with the Limited Review Report for the quarter and year ended December 31, 2025. This approval was made in continuation of the company's earlier communication dated February 11, 2026, which had intimated the scheduled date of the board meeting.

The financial results were prepared in accordance with Chapter IV read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company has attached these results as Annexure I to their regulatory filing.

Regulatory Compliance

Norris Medicines Limited has committed to publishing the approved financial results in newspapers following the format prescribed under Regulation 47 of the Listing Regulations. This step ensures transparency and compliance with disclosure requirements for listed companies.

The meeting was presided over by Director Vimal D. Shah (DIN: 01506655), who digitally signed the regulatory communication on February 14, 2026. The company has requested BSE Limited to take these developments on record as part of their ongoing compliance obligations.

Historical Stock Returns for Norris Medicines